复发/难治性多发性骨髓瘤的免疫靶向治疗研究进展  

Research progress of immune targeted therapy for relapsed/refractory multiple myeloma

作　　者：王娇娇 段朝霞 WANG Jiao-jiao;DUAN Zhao-xia(Shanxi Medical University,Taiyuan 030000,China;People′s Hospital Affiliated to Shanxi Medical University,Taiyuan 030000,China)

机构地区：[1]山西医科大学,山西太原030000 [2]山西医科大学附属人民医院,山西太原030000

出　　处：《实用药物与临床》2022年第5期449-453,共5页Practical Pharmacy and Clinical Remedies

基　　金：山西省留学回国人员科技活动择优资助项目(2014)。

摘　　要：多发性骨髓瘤(MM)是血液系统常见的恶性肿瘤,近年来,随着对MM生物学特征的深入研究以及新药的研制,使MM的生存期得到明显延长,但仍无治愈疗法,多数患者会出现复发、耐药、进展,成为复发/难治性多发性骨髓瘤(RRMM)。原药的耐药及不良反应等严重影响患者的生存质量及预后。临床上急需新的治疗手段及靶点为患者提供更有效的治疗。目前,国内外多数新药处于临床试验阶段,本文就近年来RRMM靶向治疗的新药研究进展进行综述。Multiple myeloma(MM)is a common malignant tumor of the blood system.In recent years,with the in-depth study of MM biological characteristics and the development of many new drugs,the lifetime of MM has been dramatically extend.But there is no curable method,and most patients have the disease relapse,drug resistance and progression,and then have relapsed/refractory multiple myeloma(RRMM).The life quality and prognosis of patients are seriously affected by drug resistance and the adverse reactions.New clinical treatments and targets are needed urgently for more effective treatment of RRMM.At present,the majority of new drugs are in the clinical trial period at home and abroad,and this article summarizes the research progress in new drugs for targeting therapy of RRMM.

关 键 词：复发/难治性多发性骨髓 靶向药物 嵌合抗体T细胞疗法 

分 类 号：R733.3[医药卫生—肿瘤]